Introduction
In recent years, there has been a significant progress in cardiac surgery and mortality rate has been reduced due to improvement in anesthetic and surgical techniques and patient care either in operating room or in later stages of the operation. Cardio pulmonary bypass (CPB) is an integral part of the majority of cardiac surgeries, and it has made a huge change in cardiac surgery since its invention. Despite benefits of CPB in patients undergoing heart surgery, it is also associated with
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neurologic, pulmonary, metabolic and hemostatic side effects (1) (2) (3) (4) .
Although incomplete hemostasis is the most common cause of bleeding after heart surgery, clotting problems caused by CPB can be involved in creating microvascular bleeding (5) . Reducing the number and function of platelets can occur following CPB, which is because of the blood contact with oxygenator, and CPB circuit, hemodilution, activation, degranulation, aggregation and destruction of platelets caused by CPB (6-7).
Desmopressin
(1-desamino-8-D-arginine vasopressin) is a synthetic vasopressin analogue used in patients with diabetes insipidus as well as in patients with hemophilia A and Von Willebrand disease (8, 9) . This drug is used to prevent postoperative bleeding in patients with renal failure and improves platelet function and increases factor VIII and Von Willebrand factor (9-15).
Bleeding after cardiac surgery is associated with increased mortality, keeping the sternum open, risk of mediastinal infections, consumption of blood products and length of intensive care unit (ICU) stay. Therefore, it is necessary to consider preventative measures to reduce the incidence of this complication (16) . There is a controversy regarding use of desmopressin in prevention of postoperative bleeding. Hence, we aimed at assessing the preventive role of intranasal desmopressin in reducing blood loss and the need for administration of blood products after coronary artery bypass grafting (CABG) surgery under CPB, in patients receiving antiplatelet drugs before surgery.
Methods
This study has been registered in the Iranian Registry of Clinical Trials (IRCT2013092114728N1). The present study was approved by the Ethics Committee of Tabriz University of Medical Sciences, and informed consent was obtained from the patients. In this prospective clinical trial, 40 patients admitted to Shahid Madani Heart Center were recruited. Patients were included if they were supposed to undergo CABG surgery with CPB, aged over 18 years, and were on antiplatelet therapy (aspirin 80 mg daily or clopidogrel 75 mg daily) for a week before surgery. Exclusion criteria included reoperation heart surgery (other than surgery to control bleeding), history of coagulopathy, anticoagulant medication before surgery, patient disagreement, sensitivity to desmopressin, and kidney or liver diseases. Patients were divided into two groups receiving either desmopressin (case group, 20 patients) or normal saline (control group, 20 patients). All studied patients underwent CABG surgery with CPB and received lorazepam (1 mg), morphine (0.1 mg/kg IM), and promethazine (0.5 mg/kg IM) for premedication 30 minutes before surgery. After induction of general anesthesia, bleeding time (BT) was measured. After reversing heparin effect by protamine, case and control groups received desmopressin nasal spray (two puffs, 0.3 μg/kg) and normal saline spray (two puffs) into the nose in control group were given. Then the patients were transferred to the ICU.
In the ICU, blood samples were taken from patients to assess prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), platelet count, activated clotting time (ACT), and after an hour of admission BT was re-measured. After 6 hours, either desmopressin nasal spray or saline was re-administered to the groups; in total patients received four puffs of desmopressin or normal saline. Patient vital signs, blood loss, administration of blood products, prescription drugs to improve the coagulation status, serum and whole intake and output of patients, need for a second surgery to control the bleeding, remaining sternum open, mortality due to Data were presented as mean ± standard deviation (SD), or frequency (percentage). Statistical analysis was performed with SPSS 17 (SPSS, Chicago, Illinois) using independent Ttest for quantitative variables and chi-square or Fisher's exact test for qualitative variables. A P value <0.05 was considered statistically significant.
Results
Forty patients (20 patients in each group) completed the study. The mean age of all studied patients was 60.82±1.4 years (range: 38-75). Duration of ICU stay in the case group was 4±0.4 and in control group was 4±1 (P=0.05). Amount of heparin received during surgery was 240±12.24 units in the case group and 233.3±12.01 units in the control group (P=0.9). Furthermore, bleeding volume after surgery was 619.09±149.03 cc in the case group and 778.66±179.3 cc in the control group (P=0.57). The results of the study parameters are listed in Table 1 .
Discussion
According to the increasing number and extent of heart surgery, most blood products are used in cardiac surgery wards. Until a few years ago, approximately 25% of allogeneic blood products were used in cardiac surgery. The use of CPB in cardiac surgery, amount of heparin used to prevent clotting in the CPB circuit, extent of heart surgery and performing heart surgery for the second, third and even fourth time all lead to hemostasis and coagulation disorders and increased bleeding during and after surgery. Postoperative bleeding is a complication that increases morbidity and mortality and is associated with various factors such as reduced heparin neutralization, thrombocytopenia and platelet function disorder, fibrinolysis, and coagulation factors dysfunction (17) . CPB temperature is among the factors that associate with bleeding and clotting disorders after cardiac surgery. Hypothermia has proven effects on the coagulation system; hypothermia in the range of commonly used during CPB (22-25°C) causes reversible impaired platelet function and inhibition of activated coagulation factors (18, 19) . Some believe that CPB performed in normothermic conditions results in improved coagulation factors performance and homeostasis maintenance, hence reduced postoperative bleeding. In the present study, the mean body temperature of patients during and after the operation was similar in the case and control groups. In the present study, patients receiving either desmopressin or saline were comparable in terms of the use of blood products, and blood coagulation parameters (e.g., BT, PT, PTT, INR, and platelet count).
In our study, we found no difference in total amount of postoperative bleeding in patients receiving either desmopressin or saline. Likewise, Temeck et al. (20) and Brown and colleagues (21) failed to detect any difference in bleeding between groups receiving desmopressin or placebo within the first 24 hours after cardiac surgery. Furthermore, Marquez and coworkers concluded that routine administration of desmopressin infusion vs. single dose in contrast to a single dose had no priority in reducing bleeding after CABG surgery (22) . Nonetheless, Salzman and colleagues (23), and Dilthey et al. (24) reported that desmopressin reduced the amount of bleeding during and after surgery.
Limited side effects of desmopressin are indicated in several studies including drowsiness, headache, nausea, vomiting, weight gain, mild increase in blood pressure, fluid retention, nose bleeding, and decreased blood sodium. The latter problem is important as it can be associated with seizures in severe cases. In our study, we found no difference between two studied groups with regard to 
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desmopressin side effects such as alteration in systolic and diastolic blood pressure of patients, and fluid retention (indicated by 24h urinary output).
In conclusion, desmopressin has no significant effect on reducing the amount of bleeding after cardiac surgery in patients receiving anti-platelet agents.
